

**CLAIMS**

1. Hybrid promoter comprising:
  - a) a PPAR response element and
  - 5 b) the whole or part of the promoter of the PLA2s gene.
2. Promoter according to claims 1, characterized in that the PPAR response element (a) comprises one or more PPAR-binding sites.
- 10 3. Promoter according to claim 2, characterized in that the PPAR response element (a) comprises one or more sites having the sequence SEQ ID NO:1 or functional variants of this sequence.
4. Promoter according to claim 3, characterized in that the PPAR response element
- 15 (a) comprises the sequence SEQ ID NO1, 2, 3 or 4 or a functional variant thereof.
5. Promoter according to any one of the preceding claims, characterized in that element b) comprises the whole or part of the sequence SEQ ID NO: 5.
- 20 6. Promoter according to any one of the preceding claims, characterized in that element b) comprises at least part of the PLA2s promoter conferring induction by interleukin-1 $\beta$ .
7. Promoter according to claim 5 or 6, characterized in that element (b) comprises at
- 25 least residues 51 to 61 of SEQ ID NO :5.

8. Promoter according to claim 5 or 6, characterized in that element (b) comprises at least residues 5 to 170 of SEQ ID NO :5.

5 9. Promoter according to claim 5 or 6, characterized in that element (b) comprises at least residues 51 to 170 of SEQ ID NO :5.

10. Promoter according to any one of the preceding claims, characterized in that element a) is positioned upstream (in 5') of element (b).

10 11. Promoter according to any one of the preceding claims, characterized in that it comprises, in addition, an element c) conferring tissue specificity.

15 12. Promoter according to claim 11, characterized in that element c) confers specificity for the chondrocytic cells, and in particular in that it comprises the whole or part of the sequence SEQ ID NO :7 or a variant thereof.

13. Nucleic acid comprising a hybrid promoter according to one of claims 1 to 12 and a gene of interest.

20 14. Nucleic acid according to claim 13, characterized in that the gene of interest is a gene encoding an anti-inflammatory product.

15. Vector comprising a hybrid promoter according to one of claims 1 to 12 or a nucleic acid according to either of claims 13 and 14.

25

16. Vector according to claim 15, characterized in that it is a plasmid.

17. Composition comprising a nucleic acid according to either of claims 13 and 14 or a vector according to claim 15.

18. Composition comprising (i) a nucleic acid according to either of claims 13 and 14 or a vector according to claim 15 and (ii) a PPAR activator, for use simultaneously, separately or spaced out over time.

19. Composition according to claim 18, characterized in that the PPAR activator is a PPAR $\gamma$  activator.

20. Composition according to claim 18, characterized in that the PPAR activator is a PPAR $\alpha$  activator.

21. Nucleic acid comprising a sequence chosen from SEQ ID NOS :2-4.

22. Nucleic acid comprising the sequence SEQ ID NO :6.

23. Use of a vector according to claim 15 for the preparation of a composition intended for inducing the expression of a gene in a tissue in an inflammatory situation.

24. Use of a vector according to claim 15 for the preparation of a composition intended for inducing the expression of a gene in a chondrocyte.

25. Cell modified by bringing into contact with a composition according to one of claims 1 to 15 or a vector according to one of claims 16 to 19.